Embecta (NASDAQ:EMBC) Issues Earnings Results, Beats Expectations By $0.29 EPS

Embecta (NASDAQ:EMBC) released its earnings results on Friday. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.29, Zacks reports. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm had revenue of $271.70 million for the quarter, compared to analyst estimates of $254.53 million. During the same quarter in the prior year, the firm posted $1.12 earnings per share. The company’s quarterly revenue was down 8.1% on a year-over-year basis. Embecta updated its FY 2026 guidance to 1.800-1.900 EPS.

Here are the key takeaways from Embecta’s conference call:

• U.S. revenue fell 24.6% year over year to approximately $121 million, reflecting weaker insulin-pen prescription trends, customer and payer mix pressure, and prior-year one-time benefits. Management said its outlook assumes no further recovery or deterioration in these market factors.
• Third-quarter revenue declined 8.1% year over year to approximately $272 million, although it improved sequentially by roughly $50 million. International revenue rose 11.5% as reported, helping offset continued U.S. weakness and anticipated softness in China.
• Owen Mumford integration is progressing as planned, adding auto-injectors, pharmaceutical services, and medical devices. Embecta sees a roughly $2.4 billion auto-injector market growing at a double-digit rate, though it is not yet providing specific revenue expectations for the Adaptis platform.
• Embecta raised fiscal 2026 adjusted operating margin guidance to 23.5%–24% from 22.25%–23.25% and adjusted EPS guidance to $1.80–$1.90 from $1.55–$1.75, citing cost controls, lower taxes and interest expense, and share repurchases.
• The company generated approximately $41 million in third-quarter free cash flow, repaid $53 million of debt, and expects to repay at least $150 million during fiscal 2026. Management said continued debt reduction will remain the primary capital-allocation priority.

Embecta Trading Up 26.3%

Shares of EMBC stock traded up $0.92 during trading hours on Friday, hitting $4.42. 5,586,683 shares of the company were exchanged, compared to its average volume of 1,179,668. The business has a 50 day moving average of $3.34 and a two-hundred day moving average of $6.66. Embecta has a 52 week low of $2.77 and a 52 week high of $15.55. The company has a market capitalization of $262.24 million, a PE ratio of 2.33 and a beta of 0.81.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio is 2.11%.

Institutional Investors Weigh In On Embecta

Institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its holdings in Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Wexford Capital LP acquired a new stake in shares of Embecta in the 3rd quarter valued at about $94,000. Tower Research Capital LLC TRC lifted its holdings in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares in the last quarter. iSAM Funds UK Ltd bought a new stake in shares of Embecta in the third quarter valued at about $115,000. Finally, Amundi acquired a new position in shares of Embecta during the fourth quarter worth about $127,000. 93.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on EMBC. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Mizuho decreased their target price on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, BTIG Research lowered Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Three analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $11.00.

Trending Headlines about Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
• Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
• Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
• Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
• Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
• Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.